Fertility research

Type 1 diabetes shortens reproductive period in women, study finds

The length of the female reproductive period (the time from the onset of menses to the final menstrual period) has important health implications. A new study compared the length of reproductive periods for women with type 1 diabetes with women without diabetes to confirm the effect diabetes has on the female reproductive system.

Photo
Silhouette of a woman (symbolic photo)

Image source: Unsplash/Molly Belle

Study results are published online in Menopause, the journal of The North American Menopause Society (NAMS).

Insulin plays a key role in regulating female reproductive function, and previous studies have shown the effect of insulin deficiency on a woman's reproductive system. Until now, however, little was known about the effect of type 1 diabetes on the age of natural menopause. This new study involving nearly 300 women compared the length of reproductive periods for women with type 1 diabetes with women without diabetes. It concluded that women with type 1 diabetes have shorter reproductive periods, with delayed menarche and earlier natural menopause as a result of insulin deficiency and hyperglycemia disrupting their reproductive system's normal function. Of note, however, is the fact that these findings only relate to women who were diagnosed with type 1 diabetes before reaching the age of menarche.

Because menopause is associated with a number of physiologic and metabolic changes, and early natural menopause is linked to increased cardiovascular disease and mortality, there is ongoing interest in identifying factors that provide some indication of when a woman will enter menopause. The researchers suggest that more research is needed to help determine modifiable factors that contribute to early menopause to improve the reproductive health of women with diabetes.

"This study found that women with the onset of type 1 diabetes before menarche were at increased risk for a shorter reproductive lifespan. Thus, these women are not only at risk for premature ovarian aging because of early onset type 1 diabetes, they are also at increased risk for cardiovascular disease, osteoporosis, and early mortality because of early natural menopause. Understanding these risks and targeting appropriate risk-reducing strategies are key to optimizing the health and quality of life of these women," says Dr. Stephanie Faubion, NAMS medical director. 


Source: North American Menopause Society

06.03.2021

Read all latest stories

Related articles

Photo

Preeclampsia

Novel biomarker discovery could help mother and baby

The discovery of two novel biomarkers, called FKBPL and CD44, has the potential to change the way preeclampsia is managed according to research published in the Journal of Clinical Endocrinology and…

Photo

Immune response in pregnant and lactating women

Mothers pass on Covid-19 protection to their babies after vaccination

In the largest study of its kind to date, researchers at Massachusetts General Hospital, Brigham and Women’s Hospital and the Ragon Institute of MGH, MIT and Harvard have found the new mRNA…

Photo

Insulin inhibitory receptor

New promising target for diabetes treatment

Researchers from Helmholtz Zentrum Muenchen, the Technical University of Munich and the German Center for Diabetes have discovered a novel and druggable insulin inhibitory receptor, named inceptor.…

Related products

Analyticon Biotechnologies AG - Urilyzer 100 Pro

Urinalysis

Analyticon Biotechnologies AG - Urilyzer 100 Pro

Analyticon Biotechnologies AG
Fujifilm Wako – Autokit Total Ketone Bodies Assay

Clinical Chemistry

Fujifilm Wako – Autokit Total Ketone Bodies Assay

FUJIFILM Wako Chemicals Europe GmbH
Greiner – VACUETTE FC Mix tube

Blood Glucose

Greiner – VACUETTE FC Mix tube

Greiner Bio-One
Lifotronic - FA-160 Immunofluorescence Analyzer

Other

Lifotronic - FA-160 Immunofluorescence Analyzer

Lifotronic Technology Co., Ltd
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH
Subscribe to Newsletter